Immupharma
IMM · AIM · Health Care · mcap £21m · 4.0p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 15 Sep 26 | New peer-reviewed publication
New peer-reviewed publication reports P140 activity in a preclinical MASH model |
−8.4% | |
| 15 Sep 26 | P140 International Patent Filing Update
ImmuPharma plc (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce that it has filed an international Patent Cooperation Treaty ("PCT") application relating to its P140 precision |
−8.4% | |
| 15 Sep 26 | Results | Half-year Results
ImmuPharma PLC (LSE:IMM), ("ImmuPharma", the Group or the "Company"), the specialist drug discovery and development company, is pleased to announce its unaudited interim results for the six months ended 30 June 2026 (the |
−8.4% |
| 10 Sep 26 | Holding | Holding(s) in Company | |
| 10 Aug 26 | Bioanalytical CRO partner for Kapiglucagon
ImmuPharma selects Kymos Group as bioanalytical CRO partner for Kapiglucagon |
−6.9% | |
| 22 Jul 26 | Thermo Fisher CDMO selected for Kapiglucagon pro
ImmuPharma selects Thermo Fisher Scientific drug product CDMO for Kapiglucagon program |
−6.7% | |
| 25 Jun 26 | 2026 Result Of Annual General Meeting
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. |
−6.8% | |
| 25 Jun 26 | ImmuPharma appoints Bachem for Kapiglucagon API
ImmuPharma appoints Bachem as API manufacturing partner for Kapiglucagon |
−6.8% | |
| 24 Jun 26 | University of Murcia research relating to P140
ImmuPharma plc (LSE AIM: IMM), the specialist drug discovery and development company, notes the recent article published in the scientific journal Autophagy, which reports early-stage research conducted by the University |
−3.2% | |
| 04 Jun 26 | Incanthera plc – Corporate Update & Board Changes
Incanthera plc - Corporate Update & Board Changes |
−3.7% | |
| 02 Jun 26 | Routine | Notice of AGM & Annual Report & Accounts | |
| 27 May 26 | Results | Final Results
for the twelve months ended 31 December 2025 |
−4.3% |
| 05 May 26 | IMM initiatesIND-Enabling Program for Kapiglucagon
ImmuPharma Initiates IND-Enabling Program for Kapiglucagon to treat Diabetes |
−3.4% | |
| 10 Apr 26 | Holding | Holding(s) in Company | |
| 09 Apr 26 | Board change | Chairman’s Open Letter to Shareholders
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, outlines below an open letter to shareholders from the Chairman, Tim McCarthy. |
+8.4% |
| 07 Apr 26 | Routine | Result of General Meeting and TVR | |
| 27 Mar 26 | P140 Program Update
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to provide an update on its auto-immune technology platform program, P140. |
+1.2% | |
| 23 Mar 26 | Fundraise | Result of WRAP Retail Offer and TVR
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, further to its Fundraising announcement published on 17 March 2026 at 7:00 a.m. |
−3.9% |
| 19 Mar 26 | Routine | Publication of Circular | |
| 18 Mar 26 | ‘Investor Meet Company’ presentation on 20 March
ImmuPharma to present live on 'Investor Meet Company' platform |
−8.3% | |
| 17 Mar 26 | Offer | WRAP Retail Offer for up to £1.5 million
WRAP Retail Offer for up to £1.5 million |
−22.2% |
| 17 Mar 26 | Fundraise | P140 Update; Fundraise, Related Party Transaction
IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF THE MATTERS CONTAINED IN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF SUCH INSIDE INFORMATION AS PERMITTED BY UK MA |
−22.2% |
| 06 Jan 26 | Holding | Holding(s) in Company | |
| 06 Jan 26 | Attending JPMorgan Conference & Biotech Showcase
IMMUPHARMA AT JP MORGAN CONFERENCE & BIOTECH SHOWCASE™ |
−4.7% | |
| 24 Nov 25 | Corporate Update
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces an update on P140 partnership discussions. |
−31.4% | |
| 04 Nov 25 | Holding | Holding(s) in Company | |
| 27 Oct 25 | Immupharma Attending Bio-europe
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that Tim McCarthy, CEO, Dr Tim Franklin, COO, and Dr Sebastien Goudreau, CSO will be attending the forthcoming Bio-Europe Confere |
−3.4% | |
| 23 Oct 25 | Launch of Website; Corporate Update
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to announce the launch of its new corporate website, marking another step in the Company's scientific and corporate evolution |
+13.5% | |
| 13 Oct 25 | Board change | Appointment of Independent Non-Executive Director
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to announce the appointment of Ketan Patel to the Board, as an independent Non-Executive Director. |
−6.3% |
| 06 Oct 25 | Holding | Holding(s) in Company |
Company filings. Not investment advice.